Showing results (311-320 of 1,072) with videos related to
Sort By:
Pageof 108
International Journal of Cardiology|March 12, 2026
Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 surveyDominick J Angiolillo, David Erlinge, Chris P Gale, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|October 7, 2015
Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitusLeonardo C Clavijo, Juan Maya, Glenn Carlson, et al.Journal of the American Heart Association|December 8, 2020
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A ReviewBimmer E Claessen, Paul Guedeney, C Michael Gibson, et al.Journal of Thrombosis and Thrombolysis|February 22, 2020
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulationDominick J Angiolillo, Deepak L Bhatt, Frank Lanza, et al.JACC. Cardiovascular Interventions|February 23, 2013
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) studyMario Leoncini, Anna Toso, Mauro Maioli, et al.The Journal of Pharmacology and Experimental Therapeutics|January 1, 2013
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activationHao-Jie Zhu, Xinwen Wang, Brian E Gawronski, et al.International Journal of Cardiology|November 26, 2020
Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMIAnne H Tavenier, Renicus S Hermanides, Enrico Fabris, et al.Journal of Thrombosis and Thrombolysis|March 13, 2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) studyFrancesco Pelliccia, Cesare Greco, Carlo Gaudio, et al.Journal of Thrombosis and Thrombolysis|July 16, 2013
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus statusMario Leoncini, Anna Toso, Mauro Maioli, et al.Recent Patents on Cardiovascular Drug Discovery|August 13, 2011
Clinical pharmacotherapy and drug development for pulmonary arterial hypertensionMassimiliano Mulè, Marilena Scarabelli, Davide Capodanno, et al.Pageof 108